30.26

2.15% 0.41

Mineralys Therapeutics Inc (MLYS)

Overview News Price History Option Chain Financials Discussions Forecast

Mineralys Therapeutics Inc stock is traded at $30.26, with a volume of 62,703. It is up +2.15% in the last 24 hours and up +10.84% over the past month. Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Previous Close:

$29.85

Open:

$30.22

24h Volume:

62,703

Relative Volume:

0.05

Market Cap:

$2.49B

Revenue:

Net Income/Loss:

$-154.65M

P/E Ratio:

-12.72

EPS:

-2.3786

Net Cash Flow:

$-142.43M

1W Performance:

+17.15%

1M Performance:

+10.84%

6M Performance:

-29.67%

1Y Performance:

+91.06%

1-Day Range:

$30.07

$30.69

1-Week Range:

$26.50

$30.69

52-Week Range:

$12.59

$47.65

Mineralys Therapeutics Inc Stock (MLYS) Company Profile

Name

Mineralys Therapeutics Inc

Sector

Healthcare (1110)

Industry

Biotechnology (618)

Phone

(888) 378-6240

Address

150 N. RADNOR CHESTER RD., RADNOR

Employee

Twitter

Next Earnings Date

2026-05-06

Latest SEC Filings

MLYS's Discussions on Twitter

Compare MLYS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MLYS Mineralys Therapeutics Inc	30.22	2.46B	0	-154.65M	-142.43M	-2.3786
VRTX Vertex Pharmaceuticals Inc	435.38	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	641.00	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	800.95	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	296.51	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.13	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-27-26	Initiated	TD Cowen	Buy
Jun-11-25	Initiated	Jefferies	Hold
Jul-10-24	Initiated	H.C. Wainwright	Buy
Apr-02-24	Initiated	Goldman	Buy
Mar-07-23	Initiated	BofA Securities	Buy
Mar-07-23	Initiated	Credit Suisse	Outperform
Mar-07-23	Initiated	Evercore ISI	Outperform
Mar-07-23	Initiated	Guggenheim	Buy
Mar-07-23	Initiated	Stifel	Buy
Mar-07-23	Initiated	Wells Fargo	Overweight

View All

Mineralys Therapeutics Inc Stock (MLYS) Latest News

May 25, 2026

Technical Reactions to MLYS Trends in Macro Strategies - Stock Traders Daily

May 25, 2026

May 22, 2026

Mineralys Therapeutics shareholders approve director elections and auditor at annual meeting - Investing.com Canada

May 22, 2026

Mineralys Therapeutics (MLYS) 2026 meeting approves directors and auditor - Stock Titan

May 22, 2026

May 20, 2026

Mineralys Therapeutics Stock Surges on Trial Hopes - TipRanks

May 20, 2026

May 19, 2026

Mineralys CMO David Rodman sells $11,488 in shares By Investing.com - Investing.com Canada

May 19, 2026

Mineralys CMO David Rodman sells $11,488 in shares - Investing.com

May 19, 2026

Mineralys (NASDAQ: MLYS) CMO exercises options and sells 417 pre-planned shares - Stock Titan

May 19, 2026

Guggenheim Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $48 - Moomoo

May 19, 2026

May 18, 2026

417‑share proposed sale by Mineralys (NASDAQ: MLYS) via cashless exercise - Stock Titan

May 18, 2026

Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) - The Manila Times

May 18, 2026

Mineralys Therapeutics announces presentation of new data from the late-stage launch-htn trial of lorundrostat - marketscreener.com

May 18, 2026

Mineralys Therapeutics Announces Presentation Of New Data From The Late-Stage Launch-Htn Trial Of Lorundrostat - TradingView

May 18, 2026

May 17, 2026

A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $42 to $56 - Moomoo

May 17, 2026

May 16, 2026

Why Mineralys Therapeutics Stock Is Sinking Today - TipRanks

May 16, 2026

Mineralys Advances Hypertension Drug Toward FDA Decision - MyChesCo

May 16, 2026

May 15, 2026

Mineralys Therapeutics (Nasdaq: MLYS) Grants Equity Awards to New Hires - MyChesCo

May 15, 2026

Mineralys Therapeutics Insider Sold Shares Worth $652,638, According to a Recent SEC Filing - Moomoo

May 15, 2026

May 14, 2026

Trading the Move, Not the Narrative: (MLYS) Edition - Stock Traders Daily

May 14, 2026

Mineralys CMO Rodman sells $652,637 in company stock By Investing.com - Investing.com Australia

May 14, 2026

May 13, 2026

David Malcom Rodman Sells 2,171 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat

May 13, 2026

Mineralys CMO Rodman sells $652,637 in company stock - Investing.com UK

May 13, 2026

Mineralys (NASDAQ: MLYS) CMO exercises options, sells 22,575 shares in 10b5-1 plan - Stock Titan

May 13, 2026

Multiple affiliate sales and option exercises at Mineralys Therapeutics (MLYS) - Stock Titan

May 13, 2026